Privacy Regs Won't Prevent PBMs From Contacting Patients, Lawyer Suggests
HHS' privacy regulations will allow PBMs to promote therapeutic switches to patients without prior patient authorization, provided the companies disclose to the patients how they were targeted, attorney David Bloch suggested during a marketing conference.
You may also be interested in...
HHS final privacy regulations specify that manufacturers can receive disclosures of protected health information from healthcare providers without patient consent only when the disclosure is made to an authorized employee for collection activities under specific FDA direction or requirement.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials